Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lin BioScienceROCO:6696 -6.18%26 EV-to-FCF is -38.64 as of Jul. 18, 2026. GuruFocus rates ROCO:6696 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 335 Biotechnology companies, Lin BioScience ranks worse than 298507.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lin BioScience's Enterprise Value is NT$56,010.31 Mil.
Lin BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1,449.62 Mil. Therefore, Lin BioScience's EV-to-FCF for today is -38.64.
The historical rank and industry rank for Lin BioScience's EV-to-FCF or its related term are showing as below:
ROCO:6696'
s EV-to-FCF Range Over the Past 10 Years
Min: -126.53 Med: -23.93 Max: -2.53
Current: -34.23
During the past 10 years, the highest EV-to-FCF of Lin BioScience was -2.53. The lowest was -126.53. And the median was -23.93.
ROCO:6696's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.51
vs ROCO:6696: -34.23
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lin BioScience's PE Ratio (TTM) for today is calculated as:
Lin BioScience's share price for today is NT$698.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lin BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-16.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lin BioScience EV-to-FCF Related Terms
Lin BioScience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Lin BioScience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6696 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Lin BioScience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lin BioScience EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lin BioScience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lin BioScience's EV-to-FCF falls into.
Lin BioScience's current Enterprise Value is NT$56,010.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lin BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1,449.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lin BioScience (ROCO:6696) has a EV-to-FCF of -38.64 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lin BioScience and its competitors. According to the industry distribution chart, Lin BioScience ranks #999999 out of 335 companies in the Biotechnology industry.
Is Lin BioScience's EV-to-FCF too high?
Lin BioScience's current EV-to-FCF is -38.64. Based on the distribution chart, Lin BioScience ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lin BioScience has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lin BioScience's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lin BioScience ranks #999999 out of 335 companies for EV-to-FCF. This places Lin BioScience in the lower half of its industry. The industry median EV-to-FCF is 15.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.51, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lin BioScience and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lin BioScience's current EV-to-FCF is -38.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lin BioScience stock overvalued right now?
Lin BioScience (ROCO:6696) has a current EV-to-FCF of -38.64. The current EV-to-FCF is -38.64. Lin BioScience's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lin BioScience (ROCO:6696), the current EV-to-FCF is -38.64 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.
26GF Score
Get the complete analysis for ROCO:6696
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6696 has been successfully added to your 
